Asensus Surgical Q4 2022 Earnings Report

Asensus Surgical EPS Results

• Actual EPS: -$0.07
• Consensus EPS: -$0.07
• Beat/Miss: Met Expectations
• One Year Ago EPS: N/A

Asensus Surgical Revenue Results

• Actual Revenue: $2.46 million
• Expected Revenue: $2.50 million
• Beat/Miss: Missed by -$40.00 thousand
• YoY Revenue Growth: N/A

Asensus Surgical Announcement Details

• Quarter: Q4 2022
• Date: 3/2/2023
• Time: N/A

Asensus Surgical (NYSEAMERICAN:ASXC), a medical device company, engages in the research, development, and sale of medical device robotics to enhance minimally invasive surgery (MIS) in the United States, Europe, the Middle East, Africa, and Asia. It digitizes the interface between the surgeon and the patient to perform performance-guided surgery for surgeons to deliver outcomes to patients. The company's products include Senhance System, a multi-port robotic surgery system that allows up to four arms to control robotic instruments and a camera for laparoscopic procedures; instruments and other products, including 3mm diameter instruments, 3mm and 5mm hooks, and articulating instruments; and Senhance ultrasonic system, an advanced energy device to deliver controlled energy to ligate and divide tissue. The company was formerly known as TransEnterix, Inc. and changed its name to Asensus Surgical, Inc. in February 2021. Asensus Surgical, Inc. is headquartered in Durham, North Carolina.